← Eichor
Study identifier: NCT06946238 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Single-fraction APBI for Early-stage Breast Cancer With Favorable Histological Subtypes (Breast-1F)

Condition: Breast Cancer  ·  Sponsor: IRCCS San Raffaele

PhaseNA
Planned participants311
Who can joinFemale, 40 Years to no upper limit
Healthy volunteersNo

About this study

This is a prospective, randomized, monocentric, non-inferiority interventional clinical study comparing an Accelerated Partial Breast Irradiation (APBI) for the surgical bed of early-stage breast cancer patients with favorable histological subtypes, using stereotactic radiotherapy in a single dose of 15.5 Gy with Simultaneous Integrated Boost (SIB) to 21 Gy (study treatment, delivered in a single fraction) versus multifractionated radiotherapy of 30 Gy in 5 fractions (standard treatment, delivered in 5 fractions).

This description comes directly from the study's public registry record.

Talk to the study team

Andrei Fodor, MD  ·  +390226437634  ·  fodor.andrei@hsr.it

Nadia G Di Muzio, Prof  ·  +390226437643  ·  dimuzio.nadia@hsr.it

Always discuss trial participation with your own doctor first.

Locations (1)

IRCCS San Raffaele Scientific InstituteMilan, ItalyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06946238